Adjuvanted HIV-1 vaccine promotes antibody-dependent phagocytic responses and protects against heterologous SHIV challenge.

Published online

Journal Article

To augment HIV-1 pox-protein vaccine immunogenicity using a next generation adjuvant, a prime-boost strategy of recombinant modified vaccinia virus Ankara and multimeric Env gp145 was evaluated in macaques with either aluminum (alum) or a novel liposomal monophosphoryl lipid A (MPLA) formulation adsorbed to alum, ALFA. Binding antibody responses were robust and comparable between arms, while antibody-dependent neutrophil and monocyte phagocytotic responses were greatly enhanced by ALFA. Per-exposure vaccine efficacy against heterologous tier 2 SHIV mucosal challenge was 90% in ALFA-adjuvanted males (P = 0.002), while alum conferred no protection. Half of the ALFA-adjuvanted males remained uninfected after the full challenge series, which spanned seven months after the last vaccination. Antibody-dependent monocyte and neutrophil phagocytic responses both strongly correlated with protection. Significant sex differences in infection risk were observed, with much lower infection rates in females than males. In humans, MPLA-liposome-alum adjuvanted gp120 also increased HIV-1-specific phagocytic responses relative to alum. Thus, next-generation liposome-based adjuvants can drive vaccine elicited antibody effector activity towards potent phagocytic responses in both macaques and humans and these responses correlate with protection. Future protein vaccination strategies aiming to improve functional humoral responses may benefit from such adjuvants.

Full Text

Duke Authors

Cited Authors

  • Om, K; Paquin-Proulx, D; Montero, M; Peachman, K; Shen, X; Wieczorek, L; Beck, Z; Weiner, JA; Kim, D; Li, Y; Mdluli, T; Shubin, Z; Bryant, C; Sharma, V; Tokarev, A; Dawson, P; White, Y; Appelbe, O; Klatt, NR; Tovanabutra, S; Estes, JD; Matyas, GR; Ferrari, G; Alving, CR; Tomaras, GD; Ackerman, ME; Michael, NL; Robb, ML; Polonis, V; Rolland, M; Eller, MA; Rao, M; Bolton, DL

Published Date

  • September 2020

Published In

Volume / Issue

  • 16 / 9

Start / End Page

  • e1008764 -

PubMed ID

  • 32881968

Pubmed Central ID

  • 32881968

Electronic International Standard Serial Number (EISSN)

  • 1553-7374

Digital Object Identifier (DOI)

  • 10.1371/journal.ppat.1008764

Language

  • eng

Conference Location

  • United States